Peter Heydemann
Neurology with Special Qualifications in Child Neurology · Chicago, ILNPI 1760419311
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,450 of the $10,930 with a category attached, or 77.3%. Sarepta Therapeutics, Inc. accounts for 76.3% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $5,461 and has fallen 89.0% since, to $600 in 2024.
Across 16 payments — averaging $683.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sarepta Therapeutics, Inc.$8K
- GW Research Limited$2K
- Acadia Pharmaceuticals Inc$734
Across 132 payments — averaging $2998.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- PTC Therapeutics, Inc.$139K
- Roche Products Limited$123K
- Hoffmann-la Roche Limited$50K
- GW Research Limited$36K
- Immedica Pharma US, Inc.$15K
- Sarepta Therapeutics, Inc.$13K
- plus $20K from 3 others
What the payments were for
- Consulting fees$8,45077%
- Speaking & faculty fees$3003%
- Travel & lodging$1,53314%
- Food & beverage$6266%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sarepta Therapeutics, Inc. | 7 | $8,341 |
| GW Research Limited | 6 | $1,855 |
| Acadia Pharmaceuticals Inc | 3 | $734 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Exondys 51$3,500
- DAYBUE$734
How this compares
$10,930 in reported general payments places this provider in the 75th percentile of 57 neurology with special qualifications in child neurology providers in Illinois.
See all neurology with special qualifications in child neurology providers in Illinois →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 12 | $72,791 |
| BriviactBrivaracetam | 12 | $27,830 |
| FycompaPerampanel | 18 | $23,053 |
| Divalproex Sodium | 38 | $6,689 |
| Lamotrigine ErLamotrigine | 15 | $6,241 |
| Carbamazepine ErCarbamazepine | 14 | $1,937 |
| DilantinPhenytoin Sodium Extended | 12 | $1,358 |
| Levocarnitine | 17 | $1,161 |
| Clobazam | 21 | $1,000 |
| Phenytoin | 11 | $309 |
| Diazepam | 15 | $179 |
Paid to pharmacies, not to this prescriber.
Other neurology with special qualifications in child neurology in Chicago
- Douglas NordliChicago$621K
- Nancy KuntzChicago$503K
- Vamshi RaoChicago$124K
- John MillichapChicago$84K
- Sookyong KohChicago$60K
- Elizabeth Berry-KravisChicago$38K
- Colleen BuhrfiendChicago$15K
- Bridget McGowanChicago$11K
- Divya DesaiChicago$3K
- Joseph CollinsChicago$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.